Latest Intelligence on Pharmaceutical Contract Research Organizations

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Genentech/Biogen Idec: Rituxan fails Phase II/III SLE trial

Rituxan, the blockbuster drug from Genentech and Biogen Idec, is the latest casualty in the systemic lupus erythematosus indication, reaffirming the complexity of this disease. In a Phase II/III trial, it was unable to demonstrate clinical efficacy in patients with SLE. Although Datamonitor believes that Rituxan will continue to be used off-label, these results make approval much more difficult.

Published By Datamonitor
01 May 2008
Expert View
Expert View

Pharmacovigilance solutions: essential for the future of healthcare

Although many newer pharmacovigilance solutions are still in the nascent stages, and despite pharmaceutical companies' reluctance to adopt them, it is becoming increasingly obvious that these tools will play an essential role in protecting public health. As drug safety regulations increase, signal detection technologies will aid in the costly act of identifying and managing adverse drug events.

Published By Datamonitor
06 Jun 2008
Expert View
Expert View

Online recruitment is streamlining clinical trials

The clinical drug trials required to ensure that the next blockbuster makes it to market often last longer than expected. The majority of these delays can be attributed to patient recruitment problems, arising from arduous processes and negative public perceptions. According to a new report by Datamonitor, however, the internet is proving to be an invaluable tool in streamlining recruitment.

Published By Datamonitor
22 Jul 2008
CommentWire
CommentWire

Takeda/J&J: EU recommendation positions Velcade for first-line myeloma approval

Velcade is likely to receive EMEA approval following a positive opinion issued by the EU Committee for Medicinal Products for Human Use for use in previously untreated multiple myeloma patients. Velcade would see considerable uptake if the drug is approved in the first-line setting, due to its proven activity and favorable safety profile compared to current treatment regimens.

Published By Datamonitor
28 Jul 2008
Expert View
Expert View

The paperless clinical trial: closer than you think

Life sciences companies globally are turning to eClinical solutions in a bid to cut costs during clinical trials. On average, life science companies spend between $12-17m yearly on mailings and copies of paper case report forms. With the implementation of eClinical solutions, a company could save anywhere from $10-15m a year on paper and postage alone, according to a new report by Datamonitor.

Published By Datamonitor
07 Aug 2008
CommentWire
CommentWire

Lilly: shifts R&D burden

Eli Lilly has announced that it will hand over a large proportion of its R&D efforts to contract research organization Covance. The deal, which involves Covance acquiring Lilly's 1,700-acre R&D site at Greenfield, is one of a number of major structural changes engineered by Lilly to improve its fiscal performance in the face of increasing market pressures, particularly the impact of generic drugs.

Published By Datamonitor
07 Aug 2008
CommentWire
CommentWire

Allergan: new data suggest Botox treats chronic migraine

Top-line Phase III clinical trial data of Botox for the prophylactic treatment of chronic migraine showed a statistically significant decrease in the number of headache days at 24 weeks. Depending on full data results expected in mid-2009, Botox could become the first approved treatment for this debilitating and largely underserved condition.

Published By Datamonitor
12 Sep 2008
CommentWire
CommentWire

Genentech/Roche: disappointing data may not spell the end for Avastin/Tarceva combination

Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer. However, there may still be a future for the drug combination within this indication, assuming data from a Phase III trial in the maintenance setting prove more positive.

Published By Datamonitor
06 Oct 2008
CommentWire
CommentWire

Genentech/Roche/Biogen Idec: Rituxan receives boost from leukemia data

Rituxan is the most successful targeted therapy drug to date, having long been established as a standard in non-Hodgkin's lymphoma treatment. Regulatory approval in chronic lymphocytic leukemia will further drive the drug's sales potential. However, sales growth may be hindered in some markets due to Rituxan's existing off-label use.

Published By Datamonitor
09 Dec 2008
CommentWire
CommentWire

GSK: renewing the HIV pipeline

GlaxoSmithKline and Idenix are to co-develop IDX899 for the treatment of HIV infection. Despite having eight marketed HIV products, GSK lost its position as market leader to Gilead in 2007. The new collaboration with Idenix will, however, help the company to maintain its share in the fiercely competitive HIV market.

Published By Datamonitor
09 Feb 2009

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.